Harvey G R, Rands A L, McHugh N J
Bath Institute for Rheumatic Diseases, Trimbridge, UK.
Clin Exp Immunol. 1996 Sep;105(3):468-74. doi: 10.1046/j.1365-2249.1996.d01-798.x.
The prevalence of autoantibodies to the three RNA polymerase (RNAP) enzymes in the sera of 249 SSc patients was measured using the technique of immunoprecipitation of 35S-methionine-labelled K562 cell extracts. Forty-six anti-RNAP sera were detected (18.5%) and three main groups were identified: anti-RNAP I/III sera (10; 4.0%), anti-RNAP I/II/III sera (15; 6.0%), and sera precipitating the phosphorylated (IIO) form of RNAP II (18; 7.2%). All sera in the third group also precipitated topoisomerase I (topo I), and six of them also precipitated the unphosphorylated (IIA) form of RNAP II. Although RNAP II/topo I multienzyme complexes may occur in cell extracts, autoreactive epitopes were shown to be located on both enzymes by a combination of antigen depletion studies, and in vitro assays which demonstrated functional inhibition of topo I activity. Furthermore, immunoblotting experiments using affinity-purified extracts demonstrated that all sera with anti-RNAP II antibodies recognized the largest RNAP II subunit in its phosphorylated form (IIo; 240 kD), whereas the unphosphorylated subunit (IIa; 220 kD) was only recognized by sera which also precipitated RNAP IIA. Therefore at least two different sites on the largest subunit of RNAP II are recognized by SSc sera, and one of these sites is unique to the phosphorylated (IIO) form.
采用对35S-甲硫氨酸标记的K562细胞提取物进行免疫沉淀的技术,检测了249例系统性硬化症(SSc)患者血清中针对三种RNA聚合酶(RNAP)的自身抗体的流行情况。检测到46份抗RNAP血清(18.5%),并确定了三个主要组:抗RNAP I/III血清(10份;4.0%)、抗RNAP I/II/III血清(15份;6.0%)以及沉淀RNAP II磷酸化(IIO)形式的血清(18份;7.2%)。第三组中的所有血清也沉淀拓扑异构酶I(topo I),其中6份还沉淀了RNAP II的未磷酸化(IIA)形式。虽然RNAP II/topo I多酶复合物可能存在于细胞提取物中,但通过抗原耗竭研究和体外试验相结合表明,自身反应性表位位于这两种酶上,体外试验证明topo I活性受到功能抑制。此外,使用亲和纯化提取物的免疫印迹实验表明,所有具有抗RNAP II抗体的血清都识别磷酸化形式(IIo;240 kD)的最大RNAP II亚基,而未磷酸化的亚基(IIa;220 kD)仅被也沉淀RNAP IIA的血清识别。因此,SSc血清识别RNAP II最大亚基上至少两个不同的位点,其中一个位点是磷酸化(IIO)形式所特有的。